Announcement

Collapse
No announcement yet.

Novel CAR-T shows ‘promising early signs of clinical efficacy’ for diffuse midline gliomas

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Novel CAR-T shows ‘promising early signs of clinical efficacy’ for diffuse midline gliomas

    Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study.



    https://www.healio.com/news/hematolo...idline-gliomas

  • #2
    I know of the 4 patients. Definately worth a try. There was some neurological side effects but they think they figured out how to handle them.

    Comment


    • #3
      Is this limited to H3K27M mutations? They referred to a patient with a spinal cord tumor but didn't mention a mutation in that case.

      Comment


      • #4
        https://clinicaltrials.gov/ct2/show/NCT04196413 requires the H3K27m mutation.

        Comment

        Working...
        X